Literature DB >> 31161270

Should Oncologists Recommend Cannabis?

Donald I Abrams1.   

Abstract

OPINION STATEMENT: Cannabis is a useful botanical with a wide range of therapeutic potential. Global prohibition over the past century has impeded the ability to study the plant as medicine. However, delta-9-tetrahydrocannabinol (THC) has been developed as a stand-alone pharmaceutical initially approved for the treatment of chemotherapy-related nausea and vomiting in 1986. The indication was expanded in 1992 to include treatment of anorexia in patients with the AIDS wasting syndrome. Hence, if the dominant cannabinoid is available as a schedule III prescription medication, it would seem logical that the parent botanical would likely have similar therapeutic benefits. The system of cannabinoid receptors and endogenous cannabinoids (endocannabinoids) has likely developed to help us modulate our response to noxious stimuli. Phytocannabinoids also complex with these receptors, and the analgesic effects of cannabis are perhaps the best supported by clinical evidence. Cannabis and its constituents have also been reported to be useful in assisting with sleep, mood, and anxiety. Despite significant in vitro and animal model evidence supporting the anti-cancer activity of individual cannabinoids-particularly THC and cannabidiol (CBD)-clinical evidence is absent. A single intervention that can assist with nausea, appetite, pain, mood, and sleep is certainly a valuable addition to the palliative care armamentarium. Although many healthcare providers advise against the inhalation of a botanical as a twenty-first century drug-delivery system, evidence for serious harmful effects of cannabis inhalation is scant and a variety of other methods of ingestion are currently available from dispensaries in locales where patients have access to medicinal cannabis. Oncologists and palliative care providers should recommend this botanical remedy to their patients to gain first-hand evidence of its therapeutic potential despite the paucity of results from randomized placebo-controlled clinical trials to appreciate that it is both safe and effective and really does not require a package insert.

Entities:  

Keywords:  Anorexia; Antitumor activity; Anxiety; Cannabidiol (CBD); Cannabis; Delta-9-tetrahydrocannabinol (THC); Insomnia; Medical marijuana; Nausea and vomiting; Pain; Sleep; Symptom management; Synergy with opiates

Year:  2019        PMID: 31161270     DOI: 10.1007/s11864-019-0659-9

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  71 in total

Review 1.  Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.

Authors:  M R Tramèr; D Carroll; F A Campbell; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

2.  Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.

Authors:  Aminah Jatoi; Harold E Windschitl; Charles L Loprinzi; Jeff A Sloan; Shaker R Dakhil; James A Mailliard; Sarode Pundaleeka; Carl G Kardinal; Tom R Fitch; James E Krook; Paul J Novotny; Brad Christensen
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

3.  Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.

Authors:  Frederike K Engels; Floris A de Jong; Alex Sparreboom; Ron A A Mathot; Walter J Loos; Jos J E M Kitzen; Peter de Bruijn; Jaap Verweij; Ron H J Mathijssen
Journal:  Oncologist       Date:  2007-03

4.  Antineoplastic activity of cannabinoids.

Authors:  A E Munson; L S Harris; M A Friedman; W L Dewey; R A Carchman
Journal:  J Natl Cancer Inst       Date:  1975-09       Impact factor: 13.506

5.  Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.

Authors:  Eyal Meiri; Haresh Jhangiani; James J Vredenburgh; Luigi M Barbato; Frederick J Carter; Hwa-Ming Yang; Vickie Baranowski
Journal:  Curr Med Res Opin       Date:  2007-03       Impact factor: 2.580

6.  Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial.

Authors:  D I Abrams; C A Jay; S B Shade; H Vizoso; H Reda; S Press; M E Kelly; M C Rowbotham; K L Petersen
Journal:  Neurology       Date:  2007-02-13       Impact factor: 9.910

7.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.

Authors:  E J Rahn; A Makriyannis; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 8.  Cannabinoids: potential anticancer agents.

Authors:  Manuel Guzmán
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

Review 9.  Cannabinoids in medicine: A review of their therapeutic potential.

Authors:  Mohamed Ben Amar
Journal:  J Ethnopharmacol       Date:  2006-03-15       Impact factor: 4.360

10.  A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.

Authors:  M Guzmán; M J Duarte; C Blázquez; J Ravina; M C Rosa; I Galve-Roperh; C Sánchez; G Velasco; L González-Feria
Journal:  Br J Cancer       Date:  2006-06-27       Impact factor: 7.640

View more
  6 in total

1.  Cannabinoid Hyperemesis Syndrome: A Case Report and Discussion Regarding Patients with Concurrent Disorders.

Authors:  Stephen Lee-Cheong; Amrita Grewal; Lukas Hestvik; Reza Rafizadeh; Christian Schütz
Journal:  Can J Hosp Pharm       Date:  2020-10-01

2.  Health care provider preferences for, and barriers to, cannabis use in cancer care.

Authors:  A McLennan; M Kerba; U Subnis; T Campbell; L E Carlson
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

3.  Vapor Cannabis Exposure Promotes Genetic Plasticity in the Rat Hypothalamus.

Authors:  Julianna N Brutman; Shuwen Zhang; Pique Choi; Yangzi Zhang; Meagan J Stotts; Jennifer Michal; Zhihua Jiang; Jon F Davis
Journal:  Sci Rep       Date:  2019-11-14       Impact factor: 4.379

4.  Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma.

Authors:  Tamara T Lah; Metka Novak; Milagros A Pena Almidon; Oliviero Marinelli; Barbara Žvar Baškovič; Bernarda Majc; Mateja Mlinar; Roman Bošnjak; Barbara Breznik; Roby Zomer; Massimo Nabissi
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

Review 5.  Cannabis, Cannabinoids and Cannabis-Based Medicines in Cancer Care.

Authors:  Donald I Abrams
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.279

Review 6.  Exploring the Use of State Medical Cannabis Legislation as a Proxy for Medical Cannabis Use Among Patients Receiving Chemotherapy.

Authors:  Laura E Gressler; Alan P Baltz; Ryan C Costantino; Julia F Slejko; Eberechukwu Onukwugha
Journal:  Curr Treat Options Oncol       Date:  2020-11-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.